Intelligence · Patent portfolio
Vertex Pharmaceuticals (Australia) Patents
Full USPTO pharma patent portfolio for Vertex Pharmaceuticals (Australia) — grant dates, expiration, and drug cross-links.
- Patents
- 991
- Expiring ≤24m
- 63
Quick answer
Vertex Pharmaceuticals (Australia) has 991 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 63 expire within 24 months — use filters for patent-cliff planning.
-
US 8841282
Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels
granted -
US 8841308
Pyrazin-2-amines useful as inhibitors of ATR kinase
granted -
US 8841337
Compounds useful as inhibitors of ATR kinase
granted -
US 8835639
Process for making modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8829204
Modulators of ATP-binding cassette transporters
granted -
US 8829030
Compounds and methods for the treatment or prevention of Flavivirus infections
granted -
US 8828996
Morpholine-spirocyclic piperidine amides as modulators of ion channels
granted -
US 8829007
Inhibitors of influenza viruses replication
granted -
US 8822681
Azaindoles useful as inhibitors of janus kinases
granted -
US 8822469
Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
granted -
US 8822451
Modulators of ATP-binding cassette transporters
granted -
US 8815866
Aminopyridine kinase inhibitors
granted -
US 8809335
Pyrazolopyrimidine kinase inhibitors
granted -
US 8809353
Quinazolines useful as modulators of voltage gated ion channels
granted -
US 8802700
Modulators of ATP-Binding Cassette transporters
granted -
US 8802844
Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
granted -
US 8802868
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
granted -
US 8796453
Processes and intermediates for producing azaindoles
granted -
US 8796312
Heteroaryl derivatives as CFTR modulators
granted -
US 8796308
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8785476
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 8785444
Thiazoles and pyrazoles useful as kinase inhibitors
granted -
US 8785640
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8779197
Aryl amides useful as inhibitors of voltage-gated sodium channels
granted -
US 8779156
Analogues for the treatment or prevention of flavivirus infections
granted -
US 8779127
Processes for preparing substituted pyrimidines
granted -
US 8765751
Compounds useful as inhibitors of ATR kinase
granted -
US 8765957
Process for making modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8765731
Benzimidazole analogues for the treatment or prevention of flavivirus infections
granted -
US 8759353
Co-crystals and pharmaceutical compositions comprising the same
granted -
US 8759335
Modulators of ATP-binding cassette transporters
granted -
US 8759389
Thiophene-carboxamides useful as inhibitors of protein kinases
granted -
US 8754224
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 8754222
Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8748612
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8741912
Deazapurines useful as inhibitors of Janus kinases
granted -
US 8742122
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
granted -
US 8741922
Solid forms of N-(4-(7-azabicyclo[2.2,1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
granted -
US 8741933
Modulators of ATP-binding cassette transporters
granted -
US 8741939
Modulators of ATP-binding cassette transporters
granted -
US 8741925
Modulators of ATP-binding cassette transporters
granted -
US 8735593
Aminopyridines useful as inhibitors of protein kinases
granted -
US 8722704
Modulators of ATP-binding cassette-transporters
granted -
US 8722889
Azaindoles useful as inhibitors of JAK and other protein kinases
granted -
US 8716338
Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
granted -
US 8710075
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8697698
Pyrazole compounds useful as protein kinase inhibitors
granted -
US 8691848
Inhibitors of caspases
granted
Frequently asked questions
How many patents does Vertex Pharmaceuticals (Australia) have?
991 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vertex Pharmaceuticals (Australia) patents expire?
63 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory